Fusion protein technologies for biopharmaceuticals: applications and challenges
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Hoboken, New Jersey
John Wiley & Sons
c2013
|
| Schlagworte: | |
| Online-Zugang: | FRO01 UBG01 URL des Erstveröffentlichers |
| Beschreibung: | Includes bibliographical references and index The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel being one of the best-selling biologics worldwide. Enbrel represents a milestone of modern therapies just as Humulin, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei |
| Beschreibung: | 1 Online-Ressource |
| ISBN: | 9781118354582 1118354583 9781118354575 1118354575 9781118354568 1118354567 9781118354599 1118354591 9781299241954 1299241956 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043395079 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 160222s2013 |||| o||u| ||||||eng d | ||
| 020 | |a 9781118354582 |c epub |9 978-1-118-35458-2 | ||
| 020 | |a 1118354583 |c epub |9 1-118-35458-3 | ||
| 020 | |a 9781118354575 |c pdf |9 978-1-118-35457-5 | ||
| 020 | |a 1118354575 |c pdf |9 1-118-35457-5 | ||
| 020 | |a 9781118354568 |c mobi |9 978-1-118-35456-8 | ||
| 020 | |a 1118354567 |c mobi |9 1-118-35456-7 | ||
| 020 | |a 9781118354599 |c electronic bk. |9 978-1-118-35459-9 | ||
| 020 | |a 1118354591 |c electronic bk. |9 1-118-35459-1 | ||
| 020 | |a 9781299241954 |c MyiLibrary |9 978-1-299-24195-4 | ||
| 020 | |a 1299241956 |c MyiLibrary |9 1-299-24195-6 | ||
| 024 | 7 | |a 10.1002/9781118354599 |2 doi | |
| 035 | |a (ZDB-35-WIC)ocn811850420 | ||
| 035 | |a (OCoLC)811850420 | ||
| 035 | |a (DE-599)BVBBV043395079 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-861 | ||
| 082 | 0 | |a 615.7 |2 23 | |
| 084 | |a VS 9400 |0 (DE-625)147728:253 |2 rvk | ||
| 245 | 1 | 0 | |a Fusion protein technologies for biopharmaceuticals |b applications and challenges |c edited by Stefan R. Schmidt |
| 264 | 1 | |a Hoboken, New Jersey |b John Wiley & Sons |c c2013 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel being one of the best-selling biologics worldwide. Enbrel represents a milestone of modern therapies just as Humulin, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei | ||
| 650 | 4 | |a Recombinant Fusion Proteins / therapeutic use | |
| 650 | 4 | |a Drug Carriers | |
| 650 | 4 | |a Immunotoxins / pharmacokinetics | |
| 650 | 4 | |a Immunotoxins / therapeutic use | |
| 650 | 4 | |a Protein Engineering | |
| 650 | 4 | |a Recombinant Fusion Proteins / pharmacokinetics | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a Biopharmaceutics |2 fast | |
| 650 | 7 | |a Pharmaceutical biotechnology |2 fast | |
| 650 | 4 | |a Drug carriers | |
| 650 | 4 | |a Immunotoxins / Therapeutic use | |
| 650 | 4 | |a Protein engineering | |
| 650 | 4 | |a Recombinant fusion proteins / Therapeutic use | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Biopharmaceutics | |
| 650 | 4 | |a Pharmaceutical biotechnology | |
| 650 | 0 | 7 | |a Pharmakokinetik |0 (DE-588)4115557-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Proteindesign |0 (DE-588)4346801-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapeutisches System |0 (DE-588)4267580-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Rekombinantes Protein |0 (DE-588)4277353-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Rekombinantes Protein |0 (DE-588)4277353-2 |D s |
| 689 | 0 | 1 | |a Proteindesign |0 (DE-588)4346801-9 |D s |
| 689 | 0 | 2 | |a Therapeutisches System |0 (DE-588)4267580-7 |D s |
| 689 | 0 | 3 | |a Pharmakokinetik |0 (DE-588)4115557-9 |D s |
| 689 | 0 | |8 2\p |5 DE-604 | |
| 700 | 1 | |a Schmidt, Stefan R. |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-0-470-64627-4 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 0-470-64627-6 |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9781118354599 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-35-WIC | ||
| 940 | 1 | |q UBG_PDA_WIC | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028813663 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9781118354599 |l FRO01 |p ZDB-35-WIC |q FRO_PDA_WIC |x Verlag |3 Volltext | |
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9781118354599 |l UBG01 |p ZDB-35-WIC |q UBG_PDA_WIC |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175974521110528 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043395079 |
| classification_rvk | VS 9400 |
| collection | ZDB-35-WIC |
| ctrlnum | (ZDB-35-WIC)ocn811850420 (OCoLC)811850420 (DE-599)BVBBV043395079 |
| dewey-full | 615.7 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.7 |
| dewey-search | 615.7 |
| dewey-sort | 3615.7 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04175nmm a2200853zc 4500</leader><controlfield tag="001">BV043395079</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160222s2013 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118354582</subfield><subfield code="c">epub</subfield><subfield code="9">978-1-118-35458-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118354583</subfield><subfield code="c">epub</subfield><subfield code="9">1-118-35458-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118354575</subfield><subfield code="c">pdf</subfield><subfield code="9">978-1-118-35457-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118354575</subfield><subfield code="c">pdf</subfield><subfield code="9">1-118-35457-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118354568</subfield><subfield code="c">mobi</subfield><subfield code="9">978-1-118-35456-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118354567</subfield><subfield code="c">mobi</subfield><subfield code="9">1-118-35456-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118354599</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-1-118-35459-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118354591</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">1-118-35459-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781299241954</subfield><subfield code="c">MyiLibrary</subfield><subfield code="9">978-1-299-24195-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1299241956</subfield><subfield code="c">MyiLibrary</subfield><subfield code="9">1-299-24195-6</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1002/9781118354599</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-35-WIC)ocn811850420</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)811850420</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043395079</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-861</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.7</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 9400</subfield><subfield code="0">(DE-625)147728:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Fusion protein technologies for biopharmaceuticals</subfield><subfield code="b">applications and challenges</subfield><subfield code="c">edited by Stefan R. Schmidt</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hoboken, New Jersey</subfield><subfield code="b">John Wiley & Sons</subfield><subfield code="c">c2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel being one of the best-selling biologics worldwide. Enbrel represents a milestone of modern therapies just as Humulin, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Recombinant Fusion Proteins / therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Carriers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunotoxins / pharmacokinetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunotoxins / therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein Engineering</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Recombinant Fusion Proteins / pharmacokinetics</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biopharmaceutics</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical biotechnology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug carriers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunotoxins / Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein engineering</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Recombinant fusion proteins / Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biopharmaceutics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical biotechnology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakokinetik</subfield><subfield code="0">(DE-588)4115557-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Proteindesign</subfield><subfield code="0">(DE-588)4346801-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapeutisches System</subfield><subfield code="0">(DE-588)4267580-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Rekombinantes Protein</subfield><subfield code="0">(DE-588)4277353-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Rekombinantes Protein</subfield><subfield code="0">(DE-588)4277353-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Proteindesign</subfield><subfield code="0">(DE-588)4346801-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Therapeutisches System</subfield><subfield code="0">(DE-588)4267580-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Pharmakokinetik</subfield><subfield code="0">(DE-588)4115557-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmidt, Stefan R.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-0-470-64627-4</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">0-470-64627-6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9781118354599</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-35-WIC</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">UBG_PDA_WIC</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028813663</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9781118354599</subfield><subfield code="l">FRO01</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">FRO_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9781118354599</subfield><subfield code="l">UBG01</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">UBG_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV043395079 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:24:49Z |
| institution | BVB |
| isbn | 9781118354582 1118354583 9781118354575 1118354575 9781118354568 1118354567 9781118354599 1118354591 9781299241954 1299241956 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028813663 |
| oclc_num | 811850420 |
| open_access_boolean | |
| owner | DE-861 |
| owner_facet | DE-861 |
| physical | 1 Online-Ressource |
| psigel | ZDB-35-WIC UBG_PDA_WIC ZDB-35-WIC FRO_PDA_WIC ZDB-35-WIC UBG_PDA_WIC |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | John Wiley & Sons |
| record_format | marc |
| spelling | Fusion protein technologies for biopharmaceuticals applications and challenges edited by Stefan R. Schmidt Hoboken, New Jersey John Wiley & Sons c2013 1 Online-Ressource txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references and index The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel being one of the best-selling biologics worldwide. Enbrel represents a milestone of modern therapies just as Humulin, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei Recombinant Fusion Proteins / therapeutic use Drug Carriers Immunotoxins / pharmacokinetics Immunotoxins / therapeutic use Protein Engineering Recombinant Fusion Proteins / pharmacokinetics MEDICAL / Pharmacology bisacsh Biopharmaceutics fast Pharmaceutical biotechnology fast Drug carriers Immunotoxins / Therapeutic use Protein engineering Recombinant fusion proteins / Therapeutic use Medizin Biopharmaceutics Pharmaceutical biotechnology Pharmakokinetik (DE-588)4115557-9 gnd rswk-swf Proteindesign (DE-588)4346801-9 gnd rswk-swf Therapeutisches System (DE-588)4267580-7 gnd rswk-swf Rekombinantes Protein (DE-588)4277353-2 gnd rswk-swf 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content Rekombinantes Protein (DE-588)4277353-2 s Proteindesign (DE-588)4346801-9 s Therapeutisches System (DE-588)4267580-7 s Pharmakokinetik (DE-588)4115557-9 s 2\p DE-604 Schmidt, Stefan R. Sonstige oth Erscheint auch als Druck-Ausgabe, Hardcover 978-0-470-64627-4 Erscheint auch als Druck-Ausgabe, Hardcover 0-470-64627-6 https://onlinelibrary.wiley.com/doi/book/10.1002/9781118354599 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Fusion protein technologies for biopharmaceuticals applications and challenges Recombinant Fusion Proteins / therapeutic use Drug Carriers Immunotoxins / pharmacokinetics Immunotoxins / therapeutic use Protein Engineering Recombinant Fusion Proteins / pharmacokinetics MEDICAL / Pharmacology bisacsh Biopharmaceutics fast Pharmaceutical biotechnology fast Drug carriers Immunotoxins / Therapeutic use Protein engineering Recombinant fusion proteins / Therapeutic use Medizin Biopharmaceutics Pharmaceutical biotechnology Pharmakokinetik (DE-588)4115557-9 gnd Proteindesign (DE-588)4346801-9 gnd Therapeutisches System (DE-588)4267580-7 gnd Rekombinantes Protein (DE-588)4277353-2 gnd |
| subject_GND | (DE-588)4115557-9 (DE-588)4346801-9 (DE-588)4267580-7 (DE-588)4277353-2 (DE-588)4143413-4 |
| title | Fusion protein technologies for biopharmaceuticals applications and challenges |
| title_auth | Fusion protein technologies for biopharmaceuticals applications and challenges |
| title_exact_search | Fusion protein technologies for biopharmaceuticals applications and challenges |
| title_full | Fusion protein technologies for biopharmaceuticals applications and challenges edited by Stefan R. Schmidt |
| title_fullStr | Fusion protein technologies for biopharmaceuticals applications and challenges edited by Stefan R. Schmidt |
| title_full_unstemmed | Fusion protein technologies for biopharmaceuticals applications and challenges edited by Stefan R. Schmidt |
| title_short | Fusion protein technologies for biopharmaceuticals |
| title_sort | fusion protein technologies for biopharmaceuticals applications and challenges |
| title_sub | applications and challenges |
| topic | Recombinant Fusion Proteins / therapeutic use Drug Carriers Immunotoxins / pharmacokinetics Immunotoxins / therapeutic use Protein Engineering Recombinant Fusion Proteins / pharmacokinetics MEDICAL / Pharmacology bisacsh Biopharmaceutics fast Pharmaceutical biotechnology fast Drug carriers Immunotoxins / Therapeutic use Protein engineering Recombinant fusion proteins / Therapeutic use Medizin Biopharmaceutics Pharmaceutical biotechnology Pharmakokinetik (DE-588)4115557-9 gnd Proteindesign (DE-588)4346801-9 gnd Therapeutisches System (DE-588)4267580-7 gnd Rekombinantes Protein (DE-588)4277353-2 gnd |
| topic_facet | Recombinant Fusion Proteins / therapeutic use Drug Carriers Immunotoxins / pharmacokinetics Immunotoxins / therapeutic use Protein Engineering Recombinant Fusion Proteins / pharmacokinetics MEDICAL / Pharmacology Biopharmaceutics Pharmaceutical biotechnology Drug carriers Immunotoxins / Therapeutic use Protein engineering Recombinant fusion proteins / Therapeutic use Medizin Pharmakokinetik Proteindesign Therapeutisches System Rekombinantes Protein Aufsatzsammlung |
| url | https://onlinelibrary.wiley.com/doi/book/10.1002/9781118354599 |
| work_keys_str_mv | AT schmidtstefanr fusionproteintechnologiesforbiopharmaceuticalsapplicationsandchallenges |